9/14/2005

An FDA advisory panel unanimously recommended disapproval of Abbott Laboratories' prostate cancer drug Xinlay, citing studies showing the drug failed to halt the cancer's advance. However, some members of the committee said they believed the drug could help certain patients.

Related Summaries